[en] Diagnostic strategy in screening for pulmonary embolism is presented. Perfusion-ventilation scintigraphy can resolve the diagnostic problem in over 80% of cases; the use of radioactive gases and radioaerosols in scintigraphy is described. In other cases, pulmonary angiography oriented according to scintigraphic data should be done

[en] Determination of the pulmonary clearance of ^99mTc-DTPA for the assessment of the status of the pulmonary membranes is described and its clinical application is discussed. The clearance is of low value for diagnosis of aetiology but is highly sensitive in the demonstration of lung involvement. 8 refs

[en] Short communication

No abstract available

[en] For almost 80 years ¹³¹I radioiodine (RAI) therapy has proven to be an efficient and well-tolerated therapeutic option in patients with Graves' disease (GD). Along with anti-thyroid drugs (ATD) and thyroidectomy, RAI is one the three major therapeutic tools for this autoimmune disease. The objective of this article is to review how RAI treatment is usually conducted in clinical routine and to discuss the main controversies surrounding this treatment in the light of recent national or international guidelines. This will be an opportunity to discuss the indications and contraindications for this treatment, its advantages and limits, and more generally its practical organization by a specialized team. (authors)

[en] Adrenal tuberculosis is rare and usually diagnosed on clinical signs of adrenal deficiency. We report here the uncommon incidental finding of an adrenal tuberculosis which was investigated in this context by radionuclide imaging with ¹³¹I-6β-iodomethyl-19-norcholesterol. Absence of adrenal uptake which has not yet been reported is discussed in terms of differential diagnosis with the CT scan results. (authors). 10 refs., 2 figs

[en] Short communication

No abstract available

No abstract available

[en] Nude mice bearing TT xenografts of 200 mm³ TMC received 1.25 or 3 nmol of BsAb anti-ACE/anti-DTPA F6-734 or 37 and 92.5 MBq of Ab F6F (ab')₂-¹³¹I and after 48 hours 37 and 92.5 MBq of di-DTPA-¹³¹I hapten. The delays necessary to double the tumoral volume were 57, 86, 44, and 65 d, respectively. With 37 and 92.5 MBq of di-DTPA-¹³¹ I, the losses of weight recorded in animals were 5%, the leukocyte nadirs were 1640 ± 838 and 1560 ± 116/mm³, respectively and those of the platelets of 940 ± 371 and 590 ± 454 10³/mm³, respectively. With 37 and 92.5 MBq of F6F (ab')₂-¹³¹I, the losses in weights were 8 and 16%, respectively, the leukocyte nadirs, 50 ± 100 and 175 ± 50/mm³, respectively and those of platelets of 715 ± 184 and 477 ± 106 10³/mm³. The two-time targeting system was also efficient and significantly less toxic than the one-time system. In the framework of a I phase protocol of RIT, 16 patients afflicted with metastatic CMT were treated with 20 to 50 mg of BsAb F6-734 and 4d after with 1.5 and 3.7 GBq of di-DTPA-¹³¹I. The doses delivered to the tumor were comprised between 6.8 and 139 Gy. Four patients presented a grade-IV hemato-toxicity between the 30 D and 40 D. The efficiency was evaluated in 8 patients: a antalgic effect was detected in 3/6 patients which presented osseous pains, a diminution of the size of adenopathies in 2 cases of which in one was higher than 50%, a calcinotinin diminution in 3 cases of which in two cases it was higher than 50%, a progression of the disease in 4 patients which presented a diffuse metastatic dissemination